Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial.
Quon HC, Ong A, Cheung P, Chu W, Chung HT, Vesprini D, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Loblaw A. Quon HC, et al. Among authors: panjwani d. Radiother Oncol. 2018 May;127(2):206-212. doi: 10.1016/j.radonc.2018.02.029. Epub 2018 Mar 15. Radiother Oncol. 2018. PMID: 29551231 Clinical Trial.
Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective Trials.
Roy S, Loblaw A, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Helou J, Zhang L, Mamedov A, Deabreu A, Quon HC. Roy S, et al. Among authors: panjwani d. Clin Oncol (R Coll Radiol). 2019 Sep;31(9):621-629. doi: 10.1016/j.clon.2019.05.001. Epub 2019 May 21. Clin Oncol (R Coll Radiol). 2019. PMID: 31126725
Two versus five stereotactic ablative radiotherapy treatments for localized prostate cancer: A quality of life analysis of two prospective clinical trials.
Alayed Y, Quon H, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Panjwani D, Helou J, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Commisso A, Commisso K, Loblaw A. Alayed Y, et al. Among authors: panjwani d. Radiother Oncol. 2019 Nov;140:105-109. doi: 10.1016/j.radonc.2019.06.018. Epub 2019 Jun 29. Radiother Oncol. 2019. PMID: 31265940
Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy.
Alayed Y, Davidson M, Quon H, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Liu SK, Panjwani D, Helou J, Musunuru HB, Pang G, Korol R, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Commisso A, Commisso K, D'Alimonte L, Ho L, Bhounr Z, Loblaw A. Alayed Y, et al. Among authors: panjwani d. Radiother Oncol. 2020 Mar;144:135-140. doi: 10.1016/j.radonc.2019.11.017. Epub 2019 Dec 3. Radiother Oncol. 2020. PMID: 31809979
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT).
Alayed Y, Quon H, Ong A, Cheung P, Chu W, Chung H, Vesprini D, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Zhang L, Mamedov A, Deabreu A, Loblaw A. Alayed Y, et al. Among authors: panjwani d. Radiother Oncol. 2020 Aug;149:8-13. doi: 10.1016/j.radonc.2020.04.039. Epub 2020 Apr 27. Radiother Oncol. 2020. PMID: 32416376 Clinical Trial.
Characteristics and outcomes of neonates hospitalised with SARS-CoV-2 infection in the UK by variant: a prospective national cohort study.
Gale C, Sharkey D, Fitzpatrick KE, Mactier H, Morelli A, Nakahara M, Hurd M, Placzek A, Knight M, Ladhani SN, Draper ES, Doherty C, Quigley MA, Kurinczuk JJ; Neonatal complications of COVID-19 Collaborative Group. Gale C, et al. Arch Dis Child Fetal Neonatal Ed. 2024 Apr 18;109(3):279-286. doi: 10.1136/archdischild-2023-326167. Arch Dis Child Fetal Neonatal Ed. 2024. PMID: 37968087 Free PMC article.
38 results